Benitec Biopharma Inc.

Menu

  • About Us
    • Overview
    • Board
    • Team
    • Corporate Directory
  • Our Science
    • Gene Silencing
    • Intellectual Property
    • Partnering
  • Our Programs
    • Areas of Research
    • Pipeline
    • Out-Licensed Programs
    • Presentations and Publications
  • For Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Media Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual Reports
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Events
  • Media Coverage
  • Email Alerts
May 15, 2023 8:00am EDT

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 08, 2023 8:05am EDT

Benitec Biopharma to Present at the OPMD International Conference

May 08, 2023 8:00am EDT

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

Feb 13, 2023 8:00am EST

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

Jan 23, 2023 9:48am EST

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Nov 10, 2022 8:00am EST

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

Sep 16, 2022 8:42am EDT

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Sep 12, 2022 10:06pm EDT

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

Sep 02, 2022 8:00am EDT

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

May 16, 2022 8:15am EDT

Benitec Biopharma Releases Q3 2022 Financial Results

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • About Us
    • Overview
    • Board
    • Team
    • Corporate Directory
  • Our Science
    • Gene Silencing
    • Intellectual Property
    • Partnering
  • Our Programs
    • Areas of Research
    • Pipeline
    • Presentations and Publications
  • For Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance

Address

Benitec Biopharma
3940 Trust Way
Hayward, CA. 94545
United States
P: +61 (0)3 8692-7222

Benitec Biopharma Inc.

By Drawhistory & Hatchet